Insights into novel emerging epigenetic drugs in myeloid malignancies

por Chandhok, Namrata S., Prebet, Thomas
Publicado 2019

Molecular characteristics and outcomes in Hispanic and non‐Hispanic patients with acute myeloid leukemia

por Bradley, Terrence, Kwon, Deukwoo, Monge, Jorge, Sekeres, Mikkael, Chandhok, Namrata, Thomassen, Amber, Swords, Ronan, Padron, Eric, Lancet, Jeff, Talati, Chetasi, Watts, Justin
Publicado 2022

In Vivo Anti-Tumor Effect of PARP Inhibition in IDH1/2 Mutant MDS/AML Resistant to Targeted Inhibitors of Mutant IDH1/2

por Gbyli, Rana, Song, Yuanbin, Liu, Wei, Gao, Yimeng, Biancon, Giulia, Chandhok, Namrata S, Wang, Xiaman, Fu, Xiaoying, Patel, Amisha, Sundaram, Ranjini, Tebaldi, Toma, Mamillapalli, Padmavathi, Zeidan, Amer M, Flavell, Richard A., Prebet, Thomas, Bindra, Ranjit S., Halene, Stephanie
Publicado 2022

E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial

por Bewersdorf, Jan Philipp, Stahl, Maximilian, Taylor, Justin, Mi, Xiaoli, Chandhok, Namrata Sonia, Watts, Justin, Derkach, Andriy, Wysocki, Mateusz, Lu, Sydney X., Bourcier, Jessie, Hogg, Simon J., Rahman, Jahan, Chaudhry, Sana, Totiger, Tulasigeri M., Abdel-Wahab, Omar, Stein, Eytan M.
Publicado 2023